European Vaccine Markets: Germany, UK, France, Spain, Italy, Rest of Europe

The European vaccines market has demonstrated growth even through tough economic times. This has mainly been due to the introduction of vaccines in untapped disease markets and government’s acceptance and willingness to pay for new products. This has encouraged market participants to increase spending in research and development.

This report, European Vaccine Markets, examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attack, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) infection, etc.; vaccines that address these conditions are discussed in Kalorama’s new report, “Emerging Vaccines: The World Market.”The report includes vaccine market stats for:

  • Adult Vaccines-Estimates and Forecasts for
    • Influenza
    • Pneumococcal
    • Meningitis/Pneumonia
    • DTaP
    • Hepatitis
    • HPV
    • Travel and Endemic
    • Others
  • Pediatric Vaccines-Estimates and Forecasts for:
    • Haemophilus influenzae type b (Hib)
    • Pneumococcal infection
    • Diphtheria
    • Tetanus
    • Pertussis (whooping cough)
    • Hepatitis A and B
    • Rotavirus
    • Polio
    • Measles
    • Mumps and Rubella
    • Varicella (chicken pox)
    • Influenza
    • Meningitis
    • Human papillomavirus (HPV)
    • Combination Vaccines
    • Others

The report also contains adult and pediatric vaccine regional market shares for the following countries:

  • United Kingdom
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe*
*In this Kalorama Information Report "Rest of Europe" is broken down in the total market summary (adult and pediatric combined) to include regional market share of the total European Vaccine market for Benelux, Scandinavia, Switzerland, Russia, Poland, Balkans, Baltic Countries, Hungary and Other

The report also includes company market shares for European adult and pediatric vaccine markets, key issues and trend affecting the industry, and detailed profiles of major vaccine competitors, including:

  • Bavarian Nordic A/S
  • Baxter International
  • Crucell
  • Emergent Biosolutions
  • GlaxoSmithKline
  • Novartis
  • Pfizer Inc.
  • Sanofi Pasteur

All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.


Future of European Flu Vaccine Market Rife with Innovation

In 2009, the adult flu vaccine market in Europe reached new heights with nearly $1.6 billion in revenues, up 81.4% from the prior year. According to healthcare market research publisher Kalorama Information's newly published European Vaccine Markets, this surge in flu vaccine sales was due to products developed to address the H1N1 flu pandemic.

Influenza vaccines are responsible for almost half of the adult vaccine market in 2010. Although Kalorama does not foresee the same kind of growth witnessed in 2009, the publisher expects strong demand for flu vaccines to continue, supported by an aging population and expanded recommendations for adult influenza vaccinations, though tempered by a near term decrease in demand for pandemic vaccines.

"The swine flu pandemic of 2009 prompted a flurry of activity in the flu vaccines market around the world, with a resulting surge in revenues," says Bruce Carlson, publisher of Kalorama Information. "This growth is unlikely to continue as governments overestimated the demand for H1N1 flu vaccines and found themselves with excess stock. Current development initiatives focus on products that protect against pandemic outbreaks, specific strains of influenza and alternative administration routes."

In May 2008, GlaxoSmithKline received European approval for Prepandrix and Pandemrix; each contains the H5N1 (avian flu) inactivated split, monovalent virus. Prepandrix is designed to be given before or at the onset of a declared influenza pandemic to prevent influenza caused by H5N1. It is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen, and to be long-lasting and active against a broad range of H5N1 strains. Pandemrix is approved for use when an H5N1 influenza pandemic has been officially declared by the WHO or European Union.

In December 2008, the European Medicines Agency (EMEA) issued a positive opinion for Baxter's CELVAPAN, the first cell culture-based H5N1 pandemic vaccine, in the European Union. CELVAPAN is made using Baxter's proprietary Vero cell technology, which speeds up the manufacturing process due to its ability to use the native virus which does not need to be modified in order to grow in chicken eggs. The shorter production time is critical in accelerating vaccine supply in response to an influenza pandemic.

Also of note are advancing efforts to develop a universal flu vaccine which would protect against multiple influenza strains, thereby significantly increasing effectiveness. While many companies over the years have investigated methods to achieve this, U.K.-based Immune Targeting Systems, with funding from a broad range of investors including Novartis's venture capital group, is expected to begin studies of a product candidate in 2010.

More information on flu and other types of vaccines in the European market can be found in Kalorama Information's European Vaccine Markets. This report presents market estimates and forecasts, product reviews and pipelines, issues and trends, and company profiles for pediatric and adult vaccines.

TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY

  • THE EUROPEAN VACCINES MARKET
    • Scope and Methodology
    • Overview
    • Pediatric Preventative Vaccines
  • Adult Preventative Vaccines
  • Total Market
  • Issues and Trends
CHAPTER TWO: INTRODUCTION TO VACCINES
  • A Brief History: The Development of Vaccines
  • The Immune Response
  • Mechanism of Action
  • Types of Vaccines
    • Attenuated (Weakened) Live Viruses
    • Killed (Inactivated) Viruses
    • Toxoid Vaccines
  • Genetically Engineered/Modified Vaccines
    • Subunit Vaccines
    • Conjugate Vaccines
    • DNA Vaccination
  • Vaccine Approval Process
CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
  • Introduction
    • United Nations Initiatives
  • Pediatric Vaccine Products
    • BCG
    • Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio
    • Diphtheria
    • Pertussis
    • Tetanus
    • Hepatitis B
    • Poliomyelitis
    • Haemophilus Influenzae Type B
    • Hepatitis A
    • Measles, Mumps and Rubella
    • Measles
    • Mumps
    • Rubella
    • Meningococcal Disease
    • Pneumococcal Conjugate
    • Rotavirus
    • Varicella
  • Pediatric Vaccines in Development
  • The European Market for Pediatric Preventive Vaccines
    • Total European Market Size and Forecast
    • European Market by Product Type
    • Haemophilus Influenzae Type B (Hib)
    • Pneumococcal
    • DTaP
    • Hepatitis A & B
    • Rotavirus
    • Polio
    • MMR
    • Varicella
    • Influenza
    • Menigococcal
    • HPV
    • Combinations
    • Others
    • Major Manufacturer’s Market Share—Pediatric Vaccines
CHAPTER FOUR: ADULT PREVENTIVE VACCINES
  • Introduction
  • Adult Vaccine-Preventable Diseases: Facts and Figures
  • Recommendations for Adult Immunization
    • WHO International Health Regulations
  • Adult Vaccine Products
    • BCG
    • Cervical Cancer
    • Cholera
    • Diphtheria-Tetanus
    • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Influenza
    • Pneumococcal Disease
    • Rabies
    • Shingles
    • Typhoid Fever
  • Adult Vaccines in Development
  • The European Market for Adult Preventive Vaccines
    • Total European Market Size and Forecast
    • European Market by Product Type
    • Influenza
    • DTaP Booster
    • HPV
    • Hepatitis
    • Meningitis/Pneumonia
    • Travel/Endemic Vaccines
    • Others
    • Major Manufacturer’s Market Share—Adult Vaccines
CHAPTER FIVE: VACCINES MARKET SUMMARY
  • Trends Driving the Vaccines Market
  • Market Size and Forecast
  • Vaccine Sales by Region
  • Vaccine Market Competitors
CHAPTER SIX: ISSUES AND TRENDS
  • Vaccine Safety
    • Refusal to Immunize
    • Obesity
    • World Health Organization
    • The Future of Vaccine Safety
  • Vaccine Shortages
    • Financial incentives
    • Equitable pricing
    • Vaccine stockpiles
    • Smallpox
    • Tularemia
    • Viral Hemorrhagic Fevers
  • DNA Vaccination
  • Innovations in Vaccine Delivery Systems
    • Edible Vaccines
    • Mucosal Delivery
    • Intranasal Delivery
    • Vaccine Patches
    • Vaccine Chips
  • Innovations in Vaccine Production
    • Tobacco Plant
    • Insects
    • Nanoparticle Systems
CHAPTER SEVEN: COMPANY PROFILES
  • Bavarian Nordic A/S
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Baxter International
    • History and Lines of Business
    • Vaccine Products
    • Financial Information
  • Crucell
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Emergent Biosolutions
    • History and Lines of Business
    • Strategic Acquisition and Alliance
    • Vaccine Products
    • Financial
  • GlaxoSmithKline
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Novartis
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
  • Pfizer Inc.
    • History and Lines of Business
    • Strategic alliances
    • Vaccine Products
    • Financial Information
  • Sanofi Pasteur
    • History and Lines of Business
    • Strategic Alliances
    • Vaccine Products
    • Financial Information
COMPANY DIRECTORY

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Estimated Market Sizes for Preventive Vaccines by Target Age Group in Europe 2006 - 2014

  • Table 1-2:Estimated Market Sizes for Preventive Vaccines in Europe 2006 - 2014

CHAPTER TWO: INTRODUCTION TO VACCINES

  • Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2009 (United States)
  • Table 2-2: 1Impact of Vaccines in Europe Annual Incidence 1985 vs 2008

  • Table 2-3: Vaccine-Preventable Diseases, June 2010

CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES

  • Table 3-1: Global Immunization Rates by Vaccine Type 2008 (DPT3, BCG, HepB, Hib, Measles, Polio)

  • Table 3-2: Selected Pediatric Vaccines in Development

  • Table 3-2: Selected Pediatric Vaccines in Development

  • Table 3-3: Estimated Market Sizes for Pediatric Preventive Vaccines in Europe 2006 - 2014

  • Figure 3-1: Estimated Market Sizes for Pediatric Preventive Vaccines in Europe 2006 - 2014

  • Table 3-4: Estimated Market Sizes for Pediatric Preventive Vaccines by Type in Europe (Hib Pneumococcal, DTaP, Hepatitis B, Rotavirus, Polio, MMR, Varicella, Hepatitis A, Influenza, Menigococcal, HPV, Combinations, Others, ) 2006 - 2014

  • Figure 3-2: Estimated Market Sizes for Pediatric Preventive Vaccines by Type in Europe, by Percent (Hib Pneumococcal, DTaP, Hepatitis B, Rotavirus, Polio, MMR, Varicella, Hepatitis A, Influenza, Menigococcal, HPV, Combinations, Others, ) , 2010

  • Figure 3-3: Major Manufacturers’ Shares of the Pediatric European Preventive Vaccine Market, 2010

  • Table 3-5: 2010 European Pediatric Vaccines Market Share, by Leading Competitors
CHAPTER FOUR: ADULT PREVENTIVE VACCINES

  • Table 4-1: Universal Adult Immunization Schedule 2010

  • Table 4-2: Adult Immunization Schedule for Populations with Special Medical Conditions, 2010

  • Table 4-3: WHO Pandemic Classification Schedule

  • Table 4-4: Selected Adult Preventive Vaccines in Development, 2010

  • Table 4-5: Estimated Market Sizes for Adult Preventive Vaccines in Europe 2006 - 2014

  • Figure 4-2: Estimated Market Sizes for Adult Preventive Vaccines in Europe 2006 - 2014

  • Table 4-6: Estimated Market Sizes for Adult Preventive Vaccines by Type in Europe, by Percent(Influenza, Pneumococcal/ Meningitis/Pneumonia, DTaP, Hepatitis, HPV, Travel and Endemic, Others), 2010

  • Table 4-7: Major Manufacturer’s Market Share—Adult Vaccines

  • Table 4-8: Major Manufacturers’ Shares of the Adult European Preventive Vaccine Market, 2010

  • Figure 4-3: 2010 European Adult Vaccines Market Share, by Leading Competitors
CHAPTER FIVE: VACCINES MARKET SUMMARY

  • Table 5-1: Estimated Market Sizes for Preventive Vaccines by Target Age Group in Europe 2006 - 2014

  • Figure 5-1: Estimated Market Sizes for Preventive Vaccines in Europe 2006 - 2014

  • Figure 5-2: European Market for Vaccines Share by Type, 2006, 2010 and 2014

  • Figure 5-3: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines by European Region 2006 - 2014

  • Table 5-2: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines by European Region 2006 - 2014

  • Figure 5-4: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines by European Region, by Percent, 2010

  • Figure 5-5: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines: Top Five Countries versus Other Regions in Europe, by Percent, 2010

  • Figure 5-6: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines: Top Five Countries versus Other Regions in Europe, by Percent, 2010

  • Table 5-3: Major Manufacturers’ Shares of the Total European Preventive Vaccine Market, 2010

  • Figure 5-7: 2010 European Vaccines Market Share, by Leading Competitors

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook